Strong recovery masks input cost pressure; demerger unlocks value
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
FY26 revenue flat (2%) due to input costs and price pressure; Q1 FY27 showed strong recovery (24.5% YoY). Management delivered on dividend (+25% to ₹25/share) despite FY26 profit pressure. No prior quantified guidance to break, so no cut/maintained signals.
Optimistic
next 1–2 quarters
Optimistic
multi-year
BASF delivered a strong recovery in Q1 FY27—PAT grew 162% YoY to ₹360 Cr on volume gains and margin recovery—but management remained cautious on forward visibility. Input cost inflation, geopolitical risks (Middle East), and delayed monsoons create near-term uncertainty; however, capex investments (Cellasto, dispersions) and agricultural demerger position the rump entity for medium-term growth. No quantified guidance provided.
₹4824.3 Cr
Revenue · +24.5% YoY₹360.3 Cr
Reported PAT · +162.2% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Revenue increased by 29% from INR3,875 Cr to INR4,998 Cr
OVERSTATEDRevenue grew 24.5% YoY to INR4,824.3 Cr; difference of ~₹174 Cr (~3.6% overstated)
PBT increased 166% from INR188 Cr to INR499 Cr
METReported Net Profit of INR360.3 Cr with 162.2% YoY growth; PBT claim plausible before exceptional items and taxes
Capacity utilization 82-87% for FY26
METDelivered results support healthy operations; no contradiction found
Export sales 2-2.5% of total, translating to INR403 Cr in FY26 vs INR383 Cr prior year
METFY26 total revenue ₹15,539 Cr; 403/15,539 = 2.59%, within claimed range
Operating profit margin of 10.5%, net margin 7.4% (implied from delivered 360.3 PAT on 4824.3 revenue)
METDelivered margins align exactly with Q1 results
Earnings quality
What changed since the last call
Demerger approved by shareholders 99.99% majority
UpgradeJune 2026 approval; NCLT approval expected by end-2026. Shareholders to receive 1:1 shares in BASIL; unlocks focused agri and specialties portfolios.
Coatings business divested to Carlyle Group
NeutralSale completed June 30, 2026 (effective July 1). Proceeds ₹230 Cr received. Non-core divestment; refocuses BASF on high-margin specialties.
Dividend increased 25% to ₹25/share despite FY26 profit pressure
UpgradeDespite PBT down 9% YoY in FY26, board recommended 250% payout (vs ₹20 prior). Signal of confidence in Q1 recovery.
The Q&A
Minimal. Shareholders asked substantive questions (capex plans, demerger timeline, market share, export exposure, capacity utilization, competitive position). Management answered directly on most; deferred on forward capex and detailed market share by segment (competitive sensitivity). No evasion; tone collaborative and transparent. Strong Q&A score reflects willingness to engage.
Agri segment performance — Viraj Kacharia (analyst, institutional)
PartialDelayed/erratic monsoons impacted agri in FY26. Portfolio expanded (herbicides, insecticides, fungicides); market share grown from 3% to 7% over years. Team executed well on innovation and market share expansion despite headwinds.
Demerger rationale and listing timeline — H.B. Pouredehi (shareholder)
AnsweredDemerger intended to unlock value, enable standalone focus. BASIL listing targeted H1 2027; legal separation Jan 2027, subject to NCLT approvals and regulatory clearances.
Capacity utilization and expansion timeline — Multiple (Mascarenhas, Tiwari, Pouredehi, Trivedi)
AnsweredOverall capacity utilization 82-87% for FY26, healthy and high. Dahej Cellasto expansion completed May 2026, currently in final commissioning phase; expected live by end-2026, ahead of schedule and under budget.
Export exposure and forex risk — Vinod Agarwal, Vasudha Dakwe (shareholders)
AnsweredExport sales 2-2.5% of revenue (₹403 Cr in FY26 vs ₹383 Cr prior). Company hedges 90%+ of import payables; volatility managed via alternate sourcing and strategic procurement.
Competitive position and market share — Aloysius Mascarenhas, Himanshu Trivedi (shareholders)
PartialCompetitors vary by segment: agri (Bayer, Syngenta, Rallis, PI); dispersions (Dow, Vixen); care chemicals (Galaxy); coatings (Kansai, AkzoNobel); polyurethanes (Dow, Covestro). Aim to be top-tier in every segment where we compete.
R&D and innovation spend — C.E. Mascarenhas, Gautam Tiwari (shareholders)
PartialR&D expenditure for FY26 was ₹47.8 million. Details on pages 55-57 of annual report. Attrition overall ~5%, well below market average.
CSR and sustainability commitments — Hariram Chaudhary, Bahram Vakil (shareholder/director)
AnsweredFY26 CSR: ₹12.93 Cr (FY27 budgeted ₹13.16 Cr). Partnership with CleanMax: 75-80% renewable energy across all sites. Circular economy and waste reduction programs underway (polyurethane recycling in Kerala with Green Worms).
Future AGM format and factory visits — Multiple (Dinesh Bhatia, Bharat Shah, Hariram Chaudhary, Vasudha Dakwe)
PartialCompany decided on VC per Ministry guidelines; will comply with statutory requirements going forward and decide on future AGM format accordingly. Shareholders can request factory visits via secretarial team; dates to be arranged post-meeting.
Dividend policy and payout ratio — Hariram Chaudhary (shareholder)
DodgedFY26 dividend 250% (₹25/share) recommended despite FY26 profit decline. No explicit forward payout policy stated; decision case-by-case based on profitability and capex needs.
Guidance
No explicit FY27 revenue guidance provided
LowManagement stated: 'We will not provide any forecast or outlook regarding future business performance or financial results.' Q1 FY27 result (₹4,824 Cr) reflects volume growth and improved pricing after FY26 input cost pressures.
No explicit margin guidance; targeting high capacity utilization (82-87%+)
MediumQ1 delivered 10.5% OPM, 7.4% NPM. Management noted input costs were higher in FY26 Q4 but improved in Q1 FY27. Continued hedging of forex (90%+ of payables) and supply chain diversification to manage volatility.
Cellasto Dahej expansion ₹104 Cr (live by end-2026, ahead of schedule, under budget)
HighCompleted May 2026, in final commissioning phase. Driven by strong automotive OEM demand; supports import substitution and local-for-local strategy.
Dispersions facility Mangalore expansion (line to go live end-2027)
HighGround broken Feb 2026. Project progressing well. Expected ₹5.6+ Cr committed. Supports paints, construction chemicals, paper demand growth.
Risks the call surfaced
Supply Chain & Geopolitical
MediumManagement noted input costs elevated in FY26 Q4; operations continued, but at higher cost. Monsoons delayed Q1, reducing herbicide sprays. No production stoppage to date, but risk remains.
Agricultural Business Performance
MediumAgri sales flat 2024-26 vs industry growth. Market share at 7% is small vs Bayer, Syngenta globals. Delayed monsoons impacting FY26 and Q1 performance. Demerger planned for Jan 2027; separation risk.
Pricing Power & Input Costs
MediumFY26 PBT declined 9% despite 2% revenue growth; input cost inflation only partially recovered. Merchandise business (58% of revenue) has lower margins and limited pricing power vs OMP (42%). Energy and raw material prices volatile.
Demerger Execution
MediumDemerger approved by shareholders 99.99% (June 2026) but still requires NCLT approval (expected end-2026), regulatory clearances. Legal separation Jan 2027, listing H1 2027. Risk of delays, value destruction if standalone BASIL underperforms or market conditions deteriorate.
Forex Volatility
LowCompany hedges 90%+ of import payables but 10% unhedged exposure remains. Forex earnings ₹77 Cr vs spend ₹522 Cr (₹445 Cr net outflow in FY26). Rupee weakness vs dollar headwind.
Management
Score 8/10. Clear, structured, and transparent. Opening presentation covers macro context, FY26 results, Q1 FY27 highlights, strategic initiatives without hype. Extensive Q&A (35+ shareholders) handled directly; no deflection. Explicit disclaimer on forward guidance. Mixed. FY26 execution challenged by input costs (PBT down 9% despite 2% revenue growth); however, Q1 FY27 recovery strong (PAT +162%, OPM 10.5%). Capex execution tracking (Cellasto ahead of schedule, under budget). Demerger on track (99.99% approval, NCLT approval expected end-2026).
1 · Jan 2027
Agricultural solutions demerger legal separation (BASIL)
2 · H1 2027
BASIL listing on Indian stock exchanges
3 · Q4 FY27
Cellasto expansion Dahej commissioned (ahead of schedule, under budget)
No quantified guidance provided.
Informational and educational content only. Not investment advice.